CGE Healthcare

CGE’s pharmaceutical and healthcare segment is composed of four major healthcare groups—Huadong Medicine, Grand Pharmaceutical, Grand Life Sciences, and Leiyunshang Pharmaceutical—forming a comprehensive healthcare group with broad therapeutic coverage, a rich and diversified product portfolio, and leading technological capabilities. The segment provides more than 1,000 healthcare-related products, including pharmaceuticals, medical devices, active pharmaceutical ingredients (APIs), chemical intermediates, and science-based health products. CGE Healthcare has established a globalized R&D and manufacturing network, with a strategic focus on frontier areas such as innovative medicines, nuclear medicine diagnosis and treatment, advanced formulations, mRNA therapeutics, high-end medical devices, and full-spectrum health aesthetics. Multiple R&D technology platforms and R&D centers have been deployed worldwide. Key strategic platforms include: the Nuclear Medicine Anti-tumor Diagnosis and Treatment Platform, with dual R&D hubs in Boston and Chengdu, and production bases in Boston, Frankfurt, Singapore, and Chengdu; the Precision Interventional Diagnosis and Treatment Platform, centered in Boston with core R&D and manufacturing bases across Boston and multiple locations in China; the Full-Spectrum Health Aesthetics Platform, supported by R&D centers and manufacturing facilities in the United Kingdom, France, the Netherlands, Switzerland, Belgium, Spain, Bulgaria, and Israel; and the ADC Drug R&D Platform, featuring the proprietary amanitin-based technology platform in Heidelberg, Germany. Supported by a professional global marketing system and a well-established sales network covering major international markets, multiple products have obtained EU COS certification and U.S. FDA approval, and are marketed in numerous countries and regions worldwide, earning broad market recognition.

CGE Healthcare upholds a management philosophy that is research-based, patient-centered, and market-oriented, consistently placing innovation at the core of its strategy. By building proprietary R&D platforms, promoting industry–academia–research collaboration, and advancing international cooperation, the Group continuously launches new products, providing strong support for sustainable, high-quality corporate development. After decades of steady growth, CGE Healthcare has established a fully integrated industrial chain encompassing R&D, manufacturing, and sales. Its business portfolio spans traditional Chinese medicine, chemical pharmaceuticals, biopharmaceuticals, medical devices, and medical aesthetics, achieving coordinated development across both domestic and international markets and forming a distinctive CGE Healthcare business model.